Natera, Inc. and MyOme announced the launch of an integrated polygenic risk score (iPRS) for personalized breast cancer risk assessment. This new offering expands Natera's women's health suite of products.
The iPRS provides 5-year and lifetime breast cancer risk assessments for individuals who receive a negative test result with Natera’s Empower hereditary cancer test. This addresses a critical unmet need when the biological father is unavailable for testing, which is often recommended for carrier screening.
This collaboration leverages Natera's expertise in genetic testing to offer a more comprehensive risk assessment solution. The iPRS aims to provide valuable information to patients and clinicians for proactive health management.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.